ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Cardiovascular disease"

  • Abstract Number: 1477 • 2016 ACR/ARHP Annual Meeting

    Exploring the Inadequate Cardiovascular Disease Prevention in Inflammatory Joint Diseases: Results from a Nationwide Norwegian Project

    Eirik Ikdahl1, Silvia Rollefstad2, Grunde Wibetoe3, Anne Salberg4, Dag Magnar Soldal5, Inge C Olsen6, Tore K Kvien7, Anne Grete Semb1 and Glenn Haugeberg8, 1Preventive Cardio-Rheuma clinic, Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 2Preventive Cardio-Rheuma Clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 3Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 4Hospital for Rheumatic Diseases, Lillehammer, Norway, 5Rheumatology, Hospital of Southern Norway, Kristiansand, Norway, 6Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 7Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 8Martina Hansens Hospital, Bærum, Norway

    Background/Purpose: Antihypertensives (antiHT) and lipid lowering therapies (LLT) prevent cardiovascular disease (CVD) effectively. It has been reported that patients with rheumatoid arthritis (RA) receive suboptimal…
  • Abstract Number: 1727 • 2016 ACR/ARHP Annual Meeting

    Association Between Biologic Therapies and Major Adverse Cardiac Events or Cardiac Heart Failure in Psoriatic Arthritis or Psoriasis: A Meta-Analysis

    Benedicte Champs, Rheumatology, Medecine Toulouse Purpan Hospital, Lescure d'albigeois, France

    Association between biologic therapies and major adverse cardiac events or cardiac heart failure in psoriatic arthritis or psoriasis: a meta-analysis. 1Champs B, 1Degboe Y, 1Ruyssen-Witrand…
  • Abstract Number: 2359 • 2016 ACR/ARHP Annual Meeting

    Dose-Related Risks of Cardiovascular, Gastrointestinal, and Renal Adverse Events Associated with Meloxicam Among Patients with Osteoarthritis: An Observational Study Using US Claims Data

    Elaine Hoffman1, Deirdre M. Mladsi1, Byron Cryer2, William Hopkins3, D. Craig Brater4, Rohan Parikh1, Ravi Goyal1, Jordi Castellsague5, Dana Stafkey-Mailey6 and Clarence Young7, 1Health Economics, RTI Health Solutions, Research Triangle Park, NC, 2University of Texas Southwestern Medical School, Dallas, TX, 3Fletcher Allen Health Care, University of Vermont College of Medicine, Burlington, VT, 4Indiana University School of Medicine, Bloomington, IN, 5Epidemiology, RTI Health Solutions, Barcelona, Spain, 6Xcenda, AmerisourceBergen, Palm Harbor, FL, 7Iroko Pharmaceuticals, LLC, Philadelphia, PA

    Background/Purpose:  Safety studies have shown that risks associated with non-steroidal anti-inflammatory drugs (NSAIDs) are related to dose; however, there is little evidence regarding this dose-toxicity…
  • Abstract Number: 232 • 2016 ACR/ARHP Annual Meeting

    Impact of Gout Flare Prophylaxis and Urate-Lowering Therapy on Endothelial Function, Smooth Muscle Responsiveness and Markers of Inflammation: Results of a Prospective Observational Pilot Study

    Talia Igel1,2, Aaron Garza Romero2, Virginia Pike3, Stuart Katz4, Binita Shah5, Irina Dektiarev4, Svetlana Krasnokutsky Samuels6 and Michael H. Pillinger7, 1Monash University School of Medicine, Melbourne, Australia, 2Medicine/Rheumatology, NYU School of Medicine, New York, NY, 3Medicine/Rheumatology, NYU School of Medicine/NYU Hospital for Joint Diseases, New York, NY, 4Medicine/Cardiology, NYU School of Medicine, New York, NY, 5NYU School of Medicine, Division of Cardiology, New York, NY, 6Svetlana Krasnokutsky, NYU Hospital for Joint Diseases, New York, NY, 7NYU School of Medicine, New York, NY

    Background/Purpose: To date, most studies of gout and cardiovascular disease have been cross-sectional or retrospective, and have addressed the outcome of acute coronary syndromes. Less…
  • Abstract Number: 896 • 2016 ACR/ARHP Annual Meeting

    Risk for Cardiovascular Disease in Giant Cell Arteritis and Polymyalgia Rheumatica

    Florencia Beatriz Mollerach1, Emmanuel Bertiller1, Maria de los Angeles Gallardo2, Maximiliano José Martinez1, Marina Scolnik3, Javier Rosa1, Luis J. Catoggio4 and Enrique R. Soriano1, 1Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, 2Hospital Italiano de Buenos Aires, CABA, Argentina, 3Rheumatology Section, Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, 4Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Argentina., Buenos Aires, Argentina

    Background/Purpose:  chronic inflammatory diseases are at a substantially increased risk of cardiovascular events (CVE). Scarce data is available in patients with Giant cell arteritis (GCA)…
  • Abstract Number: 1479 • 2016 ACR/ARHP Annual Meeting

    Cardiovascular Diseases and Mortality Are Independently Influenced By Carotid Plaque Presence in Rheumatoid Arthritis: The 5-Year Prospective Study

    Jung Su Eun1, Eun Song Lee2, Jong Wan Kang1, Na Ri Kim1, Ji Hun Kim1, Jin Young Kang1, Eon Jeong Nam3 and Young Mo Kang1, 1Division of Rheumatology, Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea, The Republic of, 2Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea, The Republic of, 3Division of Rheumatology, Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, South Korea

    Background/Purpose:  Patients with rheumatoid arthritis (RA) have a higher risk of cardiovascular disease (CVD) and premature mortality, compared to the general population. Inflammatory burden and conventional…
  • Abstract Number: 1782 • 2016 ACR/ARHP Annual Meeting

    Subclinical Myocarditis in Systemic Lupus Erythematosus Patients without Cardiovascular Disease

    Laura Geraldino-Pardilla1, Thania Perez2, Sabahat Bokhari3, Joan Bathon4 and Anca D. Askanase5, 1Division of Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, 2Columbia University College of Physicians & Surgeons, New York, NY, 3Cardiology, Columbia University College of Physicians & Surgeons, NY, NY, 4Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, 5Department of Medicine, Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY

    Background/Purpose : Cardiovascular disease (CVD) remains a leading cause of death in SLE. Lupus patients have a 2-3 fold increased risk to develop heart failure…
  • Abstract Number: 2504 • 2016 ACR/ARHP Annual Meeting

    Impaired Vasodilator Function in Rheumatoid Arthritis Patients Who Flared Due to Stopping Adalimumab or Etanercept

    Gerard A Rongen1, Iris van Ingen2 and Tim L Jansen3,4, 1Internal Medicine/Pharmacology and Toxicology, Radboud UMC, Nijmegen, Netherlands, 2Rheumatology, RadboudUMC, Nijmegen, Netherlands, 3Rheumatology, VieCuri Medical Centre, Venlo, Netherlands, 4Scientific IQ HealthCare, Radboud UMC, Nijmegen, Netherlands

    Background/Purpose: Chronic inflammation in rheumatoid arthritis (RA) is associated with an increased cardiovascular risk, possibly due to disrupted vascular vasodilation. Within 12 weeks adalimumab and…
  • Abstract Number: 226 • 2015 ACR/ARHP Annual Meeting

    Prevalence of Cardiovascular Disease in Patients with Gout, Osteoarthritis or Both

    Daisy Bang1, Jinfeng Xu2, Robert T. Keenan3, Virginia Pike1, Aaron Lehmann1, Craig T. Tenner4, Daria Crittenden1, Michael H. Pillinger1 and Svetlana Krasnokutsky1, 1Medicine/Rheumatology, NYU School of Medicine/NYU Hospital for Joint Diseases, New York, NY, 2Biostatistics, New York University School of Medicine, New York, NY, 3Rheumatology, Duke University, Durham, NC, 4Medicine, NYU School of Medicine, New York, NY

    Background/Purpose: Osteoarthritis (OA) and gout are each associated with increased cardiovascular disease (CVD), but their relative impacts on CV risk are not known. We compared…
  • Abstract Number: 1498 • 2015 ACR/ARHP Annual Meeting

    Engaging Clinic Staff in Work System Redesign to Adapt a Hypertension Protocol for Rheumatology

    Edmond Ramly1, Diane Lauver2 and Christie M. Bartels3, 1Industrial and Systems Engineering, University of Wisconsin-Madison College of Engineering, Madison, WI, 2University of Wisconsin-Madison School of Nursing, Madison, WI, 3Department of Medicine, University of Wisconsin (UW) School of Medicine and Public Health (SMPH), Madison, WI

    Background/Purpose: Despite routine blood pressure (BP) measurement by clinic staff, we reported that rheumatologists discussed elevated BPs in <1/3 of visits leading to missed opportunities…
  • Abstract Number: 1563 • 2015 ACR/ARHP Annual Meeting

    Dyslipidemia and Hyperglycemia, Two Cardiometabolic Parameters, Independently Predict Poor Outcome in Early Rheumatoid Arthritis: Results from Espoir Cohort

    Claire I. Daien1, Jeremie Sellam2, Nathalie Rincheval3, Bruno Fautrel4, Alain Saraux5, Francis Berenbaum6, Jacques Morel1, Jean-Pierre Daures7 and Bernard Combe8, 1Department of rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France, 2Department of Rheumatology, Assistance Publique – Hôpitaux de Paris, Saint-Antoine Hospital, Paris, France, 3Biostatistic, EA 2415, Epidemiology unit, Montpellier, France, 4Rheumatology, AP-HP Pitié-Salpêtrière Hospital / Pierre and Marie Curie University Paris 6 GRC-08 (EEMOIS), Paris, France, 5Rheumatology Department, CHU de la Cavale Blanche, Brest Cedex, France, 6Rheumatology and Paris VI University, Saint-Antoine Hospital, Paris, France, 7Biostatistic, EA 2415 Epidemiology unit, Montpellier, France, 8Rheumatology, Hopital Lapeyronie, Montpellier, France

    Background/Purpose: Previous studies showed that obesity in patients with rheumatoid arthritis (RA) is associated with higher disease activity. Beyond obesity, cardiometabolic disturbances may impact the…
  • Abstract Number: 1972 • 2015 ACR/ARHP Annual Meeting

    Cardiovascular and Cerebrovascular Disease and Social Deprivation in Patients with Giant Cell Arteritis

    Joanna Robson1, Amit Kiran2, Andrew Hutchings3, Joseph Maskell4, Nigel K Arden5, Willie Hamilton6, Bhaskar Dasgupta7,8 and Raashid Luqmani9, 1Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, University of Oxford, Oxford, United Kingdom, 2Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science, University of Oxford, Oxford, United Kingdom, 3Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, United Kingdom, 4Faculty of Medicine, University of Southampton, Southampton, United Kingdom, 5Oxford NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, United Kingdom, 6Primary Care, University of Exeter, Exeter, United Kingdom, 7Southend University Hospital, Southend, United Kingdom, 8Rheumatology, Southend University Hospital, Essex, United Kingdom, 9Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom

    Background/Purpose: Giant cell arteritis (GCA) is the most common form of vasculitis in the UK, with an incidence of 2.2 cases per 10,000 person-years. Cerebrovascular…
  • Abstract Number: 2892 • 2015 ACR/ARHP Annual Meeting

    Statin Treatment in Patients with Ankylosing Spondylitis

    Grunde Wibetoe1, Eirik Ikdahl1, Tore K. Kvien2, Silvia Rollefstad1 and Anne Grete Semb3, 1Preventive Cardio-Rheuma Clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 2Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 3Preventive Cardio-Rheuma clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway

    Background/Purpose:  Patients with ankylosing spondylitis (AS) have increased risk of cardiovascular disease (CVD). In the general population, CVD risk reduction can be achieved by lipid…
  • Abstract Number: 231 • 2015 ACR/ARHP Annual Meeting

    Uric Acid Levels Predict Mortality in Women

    Jenni E Kauppi1, Tuomo Nieminen2,3, Mika Kähönen4,5, Anne Kerola6, Antti Jula7, Jaana Leiviskä8 and Markku J. Kauppi9,10, 1School of medicine, University of Tampere, Tampere, Finland, 2Department of Internal Medicine, South Karelia Central Hospital, Lappeenranta, Finland, 3Division of Cardiology, Helsinki University Central Hospital, Helsinki, Finland, 4Department of Clinical physiology, School of Medicine, University of Tampere, Tampere, Finland, 5Department of Clinical Physiology, Medical Imaging Centre, Pirkanmaa Hospital District, Tampere, Finland, 6Faculty of Medicine, University of Helsinki, Helsinki, Finland, 7Department of Health, National Institute for Health and Welfare, Turku, Finland, 8Department of Health, National Institute for Health and Welfare, Helsinki, Finland, 9School of Medicine, University of Tampere, Tampere, Finland, 10Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland

    Background/Purpose: Hyperuricemia induces chronic inflammation and is associated with many diseases such as metabolic syndrome, high blood pressure, chronic kidney disease and cardiovascular diseases. The…
  • Abstract Number: 1503 • 2015 ACR/ARHP Annual Meeting

    A Systematic Screening of Comorbidities By the Rheumatologist in Inflammatory Rheumatisms Impacts Chronic Disease Care

    Claire I. Daien1, Amandine Tubery2, Guilhem du Cailar3, Aurore Royanez4, Thibault Mura5, Marie-Christine Picot6, Rodolphe Bourret7, François Roubille8, Jean Bousquet9, Jacques Morel1, Pierre Fesler3 and Bernard Combe10, 1Department of rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France, 2Nîmes University Hospital, Rheumatology Department, Nimes, France, 3Internal Medicine and Hypertension, Hopital Lapeyronie, Montpellier, France, 4Rheumatology and Pharmacology, Montpellier, France, 5CIC, Hopital Gui De Chauliac, Montpellier, France, 6DIM, Montpellier, France, 7Direction Teaching hospital, Montpellier, France, 8Cardiology, Montpellier, France, 9Pneumology, Montpellier, France, 10Rheumatology, Hopital Lapeyronie, Montpellier, France

    Background/Purpose: Patients with inflammatory rheumatisms especially rheumatoid arthritis (RA) have a greater risk of cardiovascular diseases (CVD), infections, chronic respiratory diseases (CRD) and osteoporosis. As…
  • « Previous Page
  • 1
  • …
  • 17
  • 18
  • 19
  • 20
  • 21
  • …
  • 38
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology